RxDoctor Payments Data

Malgorzata Witek

Psychiatry · New York, NYNPI 1518088616

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,867, more than ten times the $49 reported in 2019.

$3,694in general payments, 2019–2025

Across 154 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$738
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$660
  • Collegium Pharmaceutical, Inc.$284
  • Johnson & Johnson$239
  • Supernus Pharmaceuticals, Inc.$233
  • Otsuka America Pharmaceutical, Inc.$231
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,63398%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,694 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024
$12,062
Medicare patients
12
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl46$7,326
Bupropion XlBupropion Hcl36$710
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$663
Quetiapine Fumarate102$574
Escitalopram Oxalate97$479
Duloxetine Hcl17$382
Naltrexone Hcl12$361
Gabapentin28$351
Buspirone Hcl14$345
Prazosin Hcl15$290
Mirtazapine12$273
Trazodone Hcl56$224
Aripiprazole16$196
Zolpidem Tartrate ErZolpidem Tartrate13$166
Venlafaxine Hcl ErVenlafaxine Hcl25$166

Paid to pharmacies, not to this prescriber.

Other psychiatry in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →